You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR CABERGOLINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cabergoline

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00033111 ↗	A Study of Cabergoline for the Treatment of Cocaine Dependence - 1	Completed	University of California, Los Angeles	Phase 2	2001-06-01	The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
NCT00033111 ↗	A Study of Cabergoline for the Treatment of Cocaine Dependence - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2001-06-01	The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	GE Healthcare	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	Pfizer	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	Institute for Neurodegenerative Disorders	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Cabergoline

Condition Name

Chart
Table

Condition Name for Cabergoline
Intervention	Trials
Acromegaly	7
Ovarian Hyperstimulation Syndrome	5
Infertility	4
Lactation Suppressed	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Cabergoline
Intervention	Trials
Ovarian Hyperstimulation Syndrome	11
Acromegaly	7
Pituitary Neoplasms	6
Prolactinoma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Cabergoline

Trials by Country

Map
Table

Trials by Country for Cabergoline
Location	Trials
United States	34
Italy	15
Brazil	14
Egypt	11
Spain	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Cabergoline
Location	Trials
California	4
Massachusetts	3
Illinois	3
Texas	3
New York	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Cabergoline

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Cabergoline
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	12
Phase 2/Phase 3	5
[disabled in preview]	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Cabergoline
Clinical Trial Phase	Trials
Completed	34
Unknown status	11
Recruiting	8
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cabergoline

Sponsor Name

Chart
Table

Sponsor Name for Cabergoline
Sponsor	Trials
Pfizer	6
Novartis Pharmaceuticals	4
National Institute on Drug Abuse (NIDA)	3
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Cabergoline
Sponsor	Trials
Other	69
Industry	20
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.